What questions should I ask before selling to Mission Pet Health in 2026?

Before signing with Mission Pet Health, ask about: how your EBITDA is calculated and what add-backs they recognize; the exact cash-at-closing percentage versus rollover equity and earnout; the duration and geographic scope of your non-compete; what clinical and operational decisions remain yours post-close; whether your practice name and brand stay; the structure and timing of your retained equity buyout; staffing protections for your existing team; and what integration changes happen in the first 12 months. Getting these in writing in the letter of intent, before exclusivity, is essential.

Will Mission Pet Health change my practice name after acquisition?

Mission Pet Health's published partnership commitments state they will not change your hospital's name, brand, logo, or community impact. Their public materials emphasize that practices keep their local identity when joining the platform. Sellers should confirm this commitment in writing in the purchase agreement and ask specifically which signage, digital, and branding elements are covered by the no-rebrand pledge.

How is the Mission Pet Health acquisition process structured from LOI to closing?

The typical PE-backed acquisition process runs from letter of intent through exclusivity, due diligence, purchase agreement negotiation, and closing — commonly 90 to 150 days from LOI to funded close. Mission Pet Health, as a large institutional buyer, runs a structured diligence process that includes financial review, operational review, and employment agreement negotiation with the seller and any associate doctors. The LOI locks in key economic terms and grants exclusivity — so sellers should negotiate the LOI carefully before signing.

Questions to Ask Before Selling to Mission Pet Health in 2026

July 8, 2026

Veterinarian reviewing an acquisition offer for their practice

Questions to Ask Before Selling to Mission Pet Health in 2026

Key takeaways

Mission Pet Health is the post-merger entity of Southern Veterinary Partners (SVP) and Mission Veterinary Partners (MVP) — the merger closed late 2024 and the unified brand launched July 21, 2025, backed by Shore Capital Partners and Silver Lake, with 930-plus locations as of mid-2026.
Their partnership model is the structural through-line — sellers commonly retain 20 to 40 percent equity in their practice at close, with a pre-negotiated buyout at year five. The retained stake’s value depends on post-close performance, so you need to understand how that’s calculated before you sign.
Mission Pet Health publishes a no-rebrand commitment — your practice name, logo, and local brand stay. Confirm this in writing in the purchase agreement, not just in marketing materials.
The EBITDA normalization method drives everything — ask exactly which add-backs they recognize before you anchor to a headline multiple, because two different normalization methods on the same practice can produce very different numbers.
A direct Mission Pet Health offer reflects what they perceive your alternatives to be — the specific structure and terms of any offer become visible through a competitive process, where multiple qualified buyers underwrite the same practice in parallel.

Most Mission Pet Health conversations I walk into with a practice owner start the same way. The owner got a call, or an email, or a lunch invitation from a friendly acquisition representative.

The approach was warm. The number sounded encouraging.

And now, a few weeks later, the owner is sitting across from me wondering whether they should sign the letter of intent that arrived in their inbox.

My answer is almost always the same. Not yet.

Not because the offer is necessarily wrong for this practice. But because signing an LOI — a letter of intent, the document that locks in key economic terms and grants the buyer a period of exclusive negotiation — before you know the right answers to a handful of critical questions is the most expensive mistake in veterinary M&A.

Mission Pet Health is one of the most active and sophisticated buyers in the US veterinary market in 2026. They have scale, infrastructure, and capital behind them.

That’s a real advantage for the right seller. But sophistication on the buyer’s side is exactly why sophistication matters on the seller’s side — and the questions below are where that starts.

For broader context on where Mission fits in the full landscape of active acquirers, see our guide to veterinary practice consolidators.

If you are weighing a Mission Pet Health approach in 2026, these are the questions that change your outcome.

The direct answer is this: before signing with Mission Pet Health, ask them in writing how they calculate EBITDA and which add-backs they recognize; exactly how the deal value splits between cash at close, retained equity, and any earnout; the specific non-compete duration and radius; which clinical and operational decisions remain yours; and what integration changes will happen in the first 12 months. Get those answers in the LOI — before exclusivity.

They become dramatically harder to negotiate after.

A veterinarian reviewing a written offer document at a desk, looking down at the page, focused, not posed — papers spread out, pen in hand, warm ambient light

Who is Mission Pet Health in 2026?

Before you can ask the right questions, you need to understand the buyer clearly. Mission Pet Health is the combined platform created by the merger of Southern Veterinary Partners (SVP) and Mission Veterinary Partners (MVP). The two groups operated independently as major PE-backed veterinary consolidators.

Their merger closed late 2024, and the unified Mission Pet Health brand launched publicly on July 21, 2025, per the company’s own press release.

The combined entity is backed by Shore Capital Partners — SVP’s founding PE sponsor — alongside Silver Lake, which co-invested approximately $4 billion in fresh equity as part of the recapitalization that financed the merger. That deal valued the combined platform at roughly $8.6 billion, based on Bloomberg and Middle Market reporting from late 2024.

The entity carries approximately $3 billion in secured debt, with a repriced $2.893 billion first lien term loan due 2031.

Scale matters here because of what it signals about how Mission Pet Health thinks about acquisitions. With 930-plus locations across 31 states as of mid-2026 — per the Four Corners Property Trust real estate transaction announced May 29, 2026 — Mission Pet Health operates at a level where individual practice integrations are part of a broader system.

Their deal team has closed hundreds of acquisitions between the two legacy platforms. They are practiced at this.

The question you’re asking is what that means for your specific practice.

The underlying acquisition philosophy comes from SVP’s founding model: a partnership-model approach that prioritizes keeping sellers engaged post-close through retained equity. Dr.

Jay Price, who founded SVP in 2014, remains CEO of Mission Pet Health, and the partnership-first positioning has carried through to the combined brand. Their public partnerships page states the company was “founded with the belief that veterinarians and their teams deserve medical autonomy alongside the best support and resources.”

That’s a meaningful commitment if it’s honored in the documents. Part of what you’re doing in due diligence is testing whether the pitch matches the purchase agreement.

What questions to ask before selling to Mission Pet Health in 2026

Here are the questions that actually move outcomes. Not a generic checklist — these are the specific categories where the gap between “I asked” and “I didn’t ask” shows up in real money and real quality of life after the close.

How do you calculate my EBITDA and which add-backs do you recognize?

EBITDA — what your practice earns in pure operating profit, before taxes and accounting choices — is the foundation that every offer multiple is applied to. The multiple means nothing until you agree on the base.

Mission Pet Health, like every PE-backed buyer, works with normalized EBITDA — that same profit number after stripping out personal expenses run through the practice: vehicles, family on payroll above market rate, owner compensation above what a hired medical director would cost. The normalization adjustments are where the negotiation lives.

Ask them directly: how do they treat owner compensation above a market-rate medical director? How do they treat equipment lease payments — are they adding those back or not?

Do they capitalize certain facility expenses or run them through EBITDA? A 0.5x difference in the normalization method on a $700,000 EBITDA practice is $350,000 of headline price at a 10x multiple.

That’s not a rounding error.

Get their normalization methodology in writing, with your specific numbers applied, before the LOI. A letter of intent that says “10x EBITDA” without specifying how EBITDA is calculated is not a real offer — it’s a placeholder that will be revisited in due diligence.

Our private equity valuation guide covers how PE buyers think about these inputs in more depth.

What is the exact deal structure — cash at close, retained equity, earnout?

A headline multiple tells you the total deal value. You need to know how it’s paid.

The 3 components are: (1) cash at close for the majority stake; (2) rollover equity — keeping a slice of ownership in the new entity instead of taking all cash at closing — which you hold until the buyout event; and (3) any earnout — part of the sale price paid later, only if the practice hits agreed performance targets after closing.

On Mission Pet Health’s partnership model, sellers commonly retain 20 to 40 percent of the practice. The retained stake’s present value depends entirely on the buyout mechanics.

The mechanics of rollover equity — what it is, how it values, and what risks it carries — are covered in our earnout and rollover equity guide. What is the buyout multiple? When does it trigger? Is there a fixed put/call or is the buyout at fair market value?

A pre-negotiated put/call at a specified multiple is a materially different economic outcome from a fair-market-value buyout that requires a new appraisal in year five.

Ask these specific questions: What percentage of total deal value is cash at close? What percentage is retained equity, and at what valuation?

What are the buyout mechanics — is it a fixed multiple, a formula, or fair market value? Is there an earnout layer, and if so, on what metric, over what period, and with what cap?

The cash-at-close reality in PE-backed deals is that the majority of total deal value flows at closing — but “majority” is doing real work there. Whether that means 60 percent or 80 percent is a concrete number worth pressing on.

Sellers who assume “most of it comes at close” without nailing the specifics are frequently surprised in due diligence.

What does your non-compete look like — duration, radius, exceptions?

A non-compete agreement in a veterinary practice sale restricts the selling veterinarian from opening or working at a competing practice within a defined radius for a defined period after closing. Every major PE-backed buyer includes one. Mission Pet Health does too.

What varies significantly is the scope. Duration in PE-backed deals typically ranges from 2 to 5 years.

The radius can be anything from 5 miles in a dense urban market to 25 miles in a rural one. The exceptions matter: can you still pursue a specialty residency?

Can you work at an emergency-only clinic? Can you do relief work?

State law matters here in ways many sellers don’t expect. California, for instance, generally does not enforce non-competes except in the context of a practice sale — so a California seller has more leverage in this negotiation than the same conversation in Texas.

The FTC’s attempt to ban non-competes was halted by federal courts in August 2024, so state law continues to govern, and it varies substantially.

Get the specific non-compete terms in the LOI — not just the duration and radius, but the full scope of restricted activities. Then have a veterinary attorney review them before you sign anything.

The non-compete is often the term sellers focus on least in the LOI and regret most in year three.

Which clinical and operational decisions remain mine?

This is the question that’s easiest to answer in the marketing materials and hardest to test until you’re inside the platform. Mission Pet Health‘s public materials are explicit: they will not “tell you how to practice veterinary medicine, change your hospital’s name, or change your team’s culture.” Their stated model separates clinical autonomy from operational support.

In practice, that boundary needs to be defined in writing. What specific decisions remain with the local medical team versus migrating to Mission Pet Health’s regional operating structure?

Who sets formulary? Who approves new hires?

Who controls scheduling? Who decides on equipment investments?

Ask them to walk you through a specific example: a significant equipment purchase, a staffing change, a protocol modification. What’s the actual approval path?

Sellers who have walked through these specifics with Mission Pet Health‘s team before signing have a better sense of what the post-close relationship actually looks like versus sellers who relied on the general commitment to autonomy.

What changes happen in the first 12 months post-close?

Integration is the most underexamined question in a practice sale. Every major buyer has a post-close integration playbook.

Asking to understand Mission Pet Health’s is reasonable and should be welcomed — it signals that you’re thinking seriously about the relationship, not just the headline number.

The categories to ask about specifically: Vendor contracts — will you need to switch to Mission Pet Health‘s preferred vendors for supplies, lab, or imaging? Billing systems — will you migrate to their practice management software, and over what timeline? HR and benefits — will your team transition to Mission Pet Health‘s benefit structure, and what does that mean for existing compensation arrangements? Reporting — what financial reporting obligations does the practice have to Mission Pet Health‘s platform?

The integration path is typically more disruptive in the first 12 to 18 months than sellers anticipate. That’s not a reason to decline a Mission Pet Health partnership — it’s a reason to understand it clearly so you can manage your team through it.

What protection does my team have, and what employment agreements are required?

Your associate veterinarians, practice manager, and long-tenured support staff are often the relationship-holders that make your practice valuable. Buyers know this too.

The practical question: will your associates be required to sign employment agreements with Mission Pet Health as a condition of closing? The answer for every major PE-backed buyer is yes.

The single largest cause of deal delays since 2023 has been associate veterinarians who decline to sign employment agreements with the acquiring entity — per today’s veterinary M&A industry commentary across multiple trade sources.

This means you need to know, before entering exclusivity, whether your associate doctors will sign. Surface that conversation early.

Ask Mission Pet Health what their employment terms look like for associate doctors — compensation structure, non-solicitation provisions, and any equity or retention incentives they offer to keep key team members. Retention bonuses paid over 2 to 3 years post-close have become standard in PE-backed transactions as a tool for stabilizing the team through the transition.

What is the holdback structure?

A holdback — a portion of the purchase price the buyer retains after closing, with funds wired directly to the seller except for that held-back portion — is a standard feature of PE-backed practice acquisition agreements. It protects the buyer against post-close indemnification claims arising from a breach of the seller’s representations and warranties.

Typical holdback duration is 12 to 18 months. The holdback percentage varies.

Ask Mission Pet Health what percentage of the deal value they hold back, for how long, and what triggers a claim against it. The quality of the seller’s representations and warranties — and the accuracy of the financial information supporting them — determines the practical risk that the holdback is drawn on.

This is an area where legal counsel is not optional. The indemnification provisions in a PE-backed purchase agreement are dense, and the reps and warranties section is where practitioners of this volume of transactions will have specific language expectations.

Understanding what you’re representing before you represent it is essential.

A veterinarian and a sell-side advisor reviewing documents together, seated at a table, looking down at a term sheet, calm focused expressions, warm light, candid not posed

A quick-reference question checklist for any Mission Pet Health conversation

The questions above map to 7 specific categories. This table organizes them for a structured conversation with Mission Pet Health’s deal team — or for comparing their answers against any other buyer in a competitive process.

Category	The question to ask
EBITDA normalization	What add-backs do you recognize? Show me your normalization on my numbers.
Deal structure	What percentage is cash at close vs retained equity vs earnout?
Retained equity buyout	Is the year-five buyout a fixed multiple, a formula, or FMV?
Non-compete scope	Duration, radius, restricted activities, state-law enforceability?
Clinical autonomy	Which specific decisions migrate to regional ops vs stay local?
Post-close integration	Vendor contracts, software migration, billing — timeline and sequence?
Team employment	What do associate employment agreements look like? What retention incentives?
Holdback	What percentage, how long, what triggers a claim?

Every one of these categories has a version that’s favorable to sellers and a version that costs them real money or quality-of-life. The difference between the two usually comes down to whether the question was asked — and documented — before the LOI was signed.

Why the LOI is where this conversation has to happen

Here’s what I’ve watched play out enough times to stop calling it a pattern and start calling it a rule. Sellers who negotiate the LOI carefully — who get specific answers to the questions above documented in that 4 to 8 page letter before they grant exclusivity — consistently have a better experience than sellers who sign a short LOI and plan to “work out the details later.”

The reason is mechanical. Once you sign an LOI, you’ve typically granted Mission Pet Health 60 to 90 days of exclusivity.

You cannot shop the deal. You cannot benchmark their terms.

The leverage that a competitive process would have created — the knowledge that other qualified buyers are underwriting your practice in parallel — is gone. You’re negotiating from a fixed position.

Specific terms that often harden against sellers between LOI and purchase agreement when they weren’t nailed down at the LOI stage: the EBITDA normalization method (which affects headline price), the percentage held back, the scope of non-compete exceptions, the specific employment terms for associates, and the earnout metrics. These are not details.

They are economics.

What does a competitive process change about your Mission Pet Health conversation?

The specific structure and terms of any Mission Pet Health offer are negotiated case by case and become visible through a competitive process. Owners considering an approach from Mission Pet Health benefit from running a structured competitive process with multiple qualified buyers underwriting the same practice in parallel.

Here’s why that’s different from just “getting another offer to compare.” When Mission Pet Health — or any sophisticated buyer — knows it’s operating in a competitive process, its calibration changes. Headline price, cash-at-close percentage, non-compete scope, retained equity buyout terms, and earnout structure are all variables.

In a single-bidder conversation, each of those defaults to the buyer’s standard position. In a competitive environment, each of them moves toward the seller’s preference because the buyer is aware of what not getting the deal costs them.

I’ve seen practices where the direct offer from a major buyer in a single conversation was a meaningfully different number from what the same practice cleared when multiple buyers ran parallel diligence. The gap tends to be larger than sellers expect.

And the gap isn’t only in the headline number — it often shows up more dramatically in cash at close, non-compete duration, and the retained-equity buyout structure.

This is what the Elite Selling System is built around: we hand-select and vet every buyer who gets to bid on your practice, the way a doorman with a velvet rope lets in only the right people — including, often, Mission Pet Health itself. The result is that Mission Pet Health’s offer in a competitive process reflects what your practice is actually worth to them, rather than what they can clear in a single-bidder room.

We cover the full mechanics of a structured process in our guide to selling a veterinary practice and in the who-to-sell-your-veterinary-practice-to comparison. The valuation baseline — what your practice should be worth before any buyer conversation — is in our veterinary practice valuation guide.

What should I do if Mission Pet Health has already approached my practice?

A direct approach from Mission Pet Health is not uncommon in 2026. At 930-plus locations with active acquisition infrastructure, they contact practices in markets where they see strategic fit.

Receiving the call doesn’t mean you need to act on it alone.

The smartest sequence: understand the approach clearly, get a baseline on your own practice’s value independently, and determine whether a competitive process would produce a better outcome before you grant exclusivity to any buyer. The cost of that step is a few weeks.

The cost of skipping it can run into seven figures on a substantial practice.

Mission Pet Health is a real and serious buyer. For the right practice in the right geography with the right seller profile, a Mission Pet Health partnership can be an excellent outcome.

The questions above are not arguments against that outcome. They’re the path to knowing whether that outcome is the best one available — or whether there’s a better number and structure somewhere in the buyer pool.

If you’ve received an approach and want an independent read on your options, that’s exactly what we do.

Get a Free Mission Pet Health Offer Review →

We’ll look at your practice’s profile, tell you what we’d expect your practice to clear in a competitive process, and give you a plain read on whether the Mission Pet Health approach you’ve received is where the conversation should end or where it should start.

There are no upfront fees. We’re compensated only when a deal closes, and only out of the value created above what the seller would have realized on their own.

If the Mission Pet Health offer is already at the top of the market for your practice, we’ll tell you that too.

Frequently asked questions

What questions should I ask Mission Pet Health before signing an LOI?

Before you sign a letter of intent with Mission Pet Health, ask: how they calculate and normalize your EBITDA; what percentage of total deal value is cash at close versus retained equity versus earnout; what the retained-equity buyout mechanics are at year five; the exact duration, radius, and scope of the non-compete; which clinical and operational decisions migrate to their regional structure versus remain local; what integration changes happen in the first 12 months; what employment agreements your associates are required to sign; and what the holdback percentage, duration, and trigger terms are. Get these in writing in the LOI — before you grant exclusivity.

What is Mission Pet Health’s partnership model?

Mission Pet Health’s partnership model allows selling veterinarians to retain a minority equity stake — typically in the 20 to 40 percent range — in their practice after the majority sale closes, with a pre-negotiated put/call buyout mechanism, commonly structured around a year-five exit. The model is designed to keep sellers invested in post-close performance.

The value of the retained stake depends on how the practice performs under Mission Pet Health’s platform and on the specific buyout mechanics negotiated at LOI.

Will Mission Pet Health change my practice name?

Mission Pet Health’s published partnership commitments state they will not change your hospital’s name, brand, logo, or community impact. Their stated model preserves local identity.

Sellers should confirm this commitment in writing in the purchase agreement — not only in marketing materials — and ask specifically which signage, digital, and branding elements are covered by the no-rebrand commitment.

How does Mission Pet Health calculate EBITDA?

Mission Pet Health, like all major PE-backed buyers, works from normalized EBITDA — your practice’s operating profit after stripping out personal expenses run through the practice, such as owner compensation above a market-rate medical director, personal vehicles, and family payroll above market rates. Their normalization method sets the base number that the offer multiple is applied to.

Ask them to show their normalization on your actual financials before the LOI is signed, because two different normalization approaches on the same practice can produce meaningfully different headline prices.

What non-compete does Mission Pet Health require?

PE-backed buyers including Mission Pet Health typically include a non-compete restricting the selling veterinarian from practicing within a defined radius for a defined period — commonly 2 to 5 years in duration. Geographic radius varies by market density.

Enforceability depends on state law; California, for instance, generally limits non-compete enforcement except in the context of a practice sale. Sellers should review the specific non-compete terms with veterinary legal counsel before signing any letter of intent.

Should I take Mission Pet Health’s direct offer or run a competitive process?

The specific structure and terms of any Mission Pet Health offer are negotiated case by case and become visible through a competitive process. Owners who receive a direct approach benefit from understanding what the same practice would clear when multiple qualified buyers underwrite it in parallel.

A competitive process creates the leverage that tends to move headline price, cash-at-close percentage, retained-equity structure, and non-compete terms simultaneously — because every buyer, including Mission Pet Health, calibrates its offer to what it perceives your alternatives to be.

What happens to my team when I sell to Mission Pet Health?

Mission Pet Health’s published materials state that sellers keep the team they have trained. In practice, all major PE-backed buyers require associate doctors to sign employment agreements with the acquiring entity as a condition of closing.

Sellers should surface associate employment intentions early — before entering exclusivity — and ask Mission Pet Health what retention bonuses, equity incentives, and employment terms they offer to key team members. The single largest cause of deal delays in 2025-2026 has been associate veterinarians who decline to sign these employment agreements.

What is a holdback in a Mission Pet Health deal?

A holdback is a portion of the purchase price the buyer retains after closing — funds that are not wired to the seller at close but held back by the buyer — for a defined period, typically 12 to 18 months, to cover any indemnification claims if the seller’s representations and warranties prove inaccurate. It is standard in PE-backed practice acquisition agreements.

Sellers should ask about the holdback percentage, duration, and the specific triggers that would allow Mission Pet Health to draw on it. Legal review of indemnification provisions before signing is essential.